Journal of Clinical Oncology
Articles in this Issue
APS-TMA phenotypes as a failure-to-rescue signal during U.S. cancer hospitalizations: National Inpatient Sample, 2018–2022.
11041 Background: Failure-to-rescue (FTR), defined as mortality following major inpatient complications, reflects both pat...
Hydroxyurea use and thrombotic outcomes in myelofibrosis patients with leukocytosis: A propensity-matched real-world analysis.
e18605 Background: Patients with myelofibrosis (MF), especially those with marked leukocytosis, face increased risk for th...
Evaluation of a novel blood-based lung nodule triage test in elevated-risk subjects.
10547 Background: In the National Lung Screening Trial (NLST), 4,354 (6%) of LDCT scans were positive with Lung RADS score...
Incidence, predictors, and recovery of acute chemotherapy-related left ventricular dysfunction in breast cancer patients: A prospective US cohort study.
e12528 Background: Advancements in breast cancer therapies, including anthracycline-based regimens and targeted agents lik...
AI-driven risk stratification for distant recurrence in node-positive HR+/HER2− early breast cancer: Independent validation in the NSABP B-28 trial.
558 Background: Accurate prediction of risk of distant recurrence (DR) in HR+, HER2-negative early-stage breast cancer (EB...
Yttrium-90 SIRT followed by lenvatinib plus sintilimab for unresectable intermediate-to-advanced hepatocellular carcinoma: Phase II SIRLENS-90 trial.
4149 Background: Selective internal radiation therapy (SIRT) with yttrium-90 microspheres is an established locoregional t...
Real-world outcomes of crizotinib treatment for ALK+ and ROS1+ metastatic non-small cell lung cancer in Nepal.
e20689 Background: Lung cancer remains the most common and most lethal cancer in Nepal. Although targeted therapies have c...
The risk of hyperglycemia with PI3K inhibitors in cancer patients: A meta-analysis.
e15128 Background: Phosphoinositide 3-kinase (PI3K) inhibitors are a promising therapeutic class in cancer treatment and t...
Distinct patient and product-specific phenotypes associated with toxicity and resource utilization after CAR T-cell therapy: A Nationwide Inpatient analysis.
11193 Background: Chimeric antigen receptor (CAR) T-cell therapy improves outcomes in relapsed or refractory hematologic m...
National trends in sepsis-related mortality among decedents with malignant neoplasms in the United States, 1999–2023.
e13506 Background: Sepsis is one of the leading causes of death in cancer patients as a result of both immunosuppression,...
Sex-specific risk of mood and anxiety disorders following cancer diagnosis in adolescents and young adults: A Canadian population-based study.
e24120 Background: Adolescents and young adults (AYAs) with cancer have unique medical and psychosocial needs. Despite imp...
A study evaluating microbiome modulation therapy in patients undergoing first-line therapy for metastatic colorectal cancer.
TPS3679 Background: Colorectal cancer (CRC) is the second leading cause of cancer-related mortality worldwide. Despite adv...
Association of SGLT2 inhibitors and GLP-1 receptor agonists or DPP-4 inhibitors with incident cancer in patients with type 2 diabetes.
10590 Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) exert potential anti-tumor effects. Emerging data sug...
Correlation of baseline testosterone (T) level with survival outcomes in patients (Pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of patient (pt)–level data from SWOG 1216 study.
5096 Background: Retrospective data suggest that low baseline serum T may be associated with inferior survival outcomes in...
Zongertinib in previously treated advanced HER2-mutant non-small cell lung cancer: A single-center study.
e20727 Background: HER2 mutations are present in 2-4% of advanced non-small cell lung cancer (NSCLC)....
Real-world effectiveness and safety of adjuvant capecitabine in triple-negative breast cancer (TNBC) patients with residual disease following neoadjuvant chemotherapy.
543 Background: The presence of residual disease in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy is...
Survival and functional outcomes in octogenarians with lung cancer.
e20099 Background: The incidence of lung cancer is increasing among octogenarians, yet this population is less likely to r...
Immune-related adverse events and patient outcomes in non–small cell lung cancer: A silver lining?
e20060 Background: Immune checkpoint inhibitor (ICI) therapy has prolonged survival in non-small cell lung cancer (NSCLC),...
Rivaroxaban versus low molecular weight heparin in cancer-associated thrombosis: Assessment of clinical equipoise and bleeding risk from randomized evidence.
e24200 Background: Direct oral anticoagulants are increasingly adopted for cancer-associated thrombosis (CAT) due to ease...
Integrating objective sarcopenia assessment into geriatric screening as a predictor of treatment tolerance.
1665 Background: Geriatric assessment (GA)–based screening tools, including the G8 screening tool, the Korean Cancer Study...
The efficacy and safety of sosimerasib monotherapy in pretreated colorectal cancer with KRAS G12C mutation: Results from a phase 1b study.
3596 Background: KRAS G12C mutation is a key driver in approximately 3-4% of colorectal cancer (CRC) cases with poor progn...
Clinical characteristics, treatment patterns, and outcomes of patients with small bowel cancer: A real-world cohort from a tertiary cancer center.
e15726 Background: Small bowel cancers (SBC) are rare malignancies accounting for < 5% of gastrointestinal (GI) cancers...
Prognostic significance of body fat in early-stage breast cancer.
e12737 Background: Body fat is increasingly recognized as a key determinant of cancer biology and clinical outcomes. Altho...
A single-center retrospective analysis of antibody-drug conjugate utilization and associated toxicities in patients with solid tumors.
e15025 Background: Antibody-drug conjugates (ADCs) are increasingly used to treat both hematologic and solid malignancies....
Transposon-engineered hypoxia-inducible T cells for treatment of solid tumors.
2565 Background: Engineered cell therapies expressing a chimeric antigen receptor (CAR) in human T cells have demonstrated...